MedTrace Logo

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012

NCT03022435 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2017-05-22

Study results available
· View outcomes & findings →

Summary

This study will investigate markers, mechanisms and define general predictors for immunological health by comparing influenza vaccine responses in monozygotic and dizygotic twins.

Conditions

Interventions

BIOLOGICAL

TIV

Influenza Virus Vaccine Suspension for Intramuscular Injection

BIOLOGICAL

High-Dose TIV

High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe

BIOLOGICAL

LAIV

Live, attenuated influenza vaccine for Intranasal Spray

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Stanford University

    lead OTHER

Principal Investigators

  • Cornelia Dekker, MD · Stanford University

  • Mark Davis, PhD · Stanford University

  • Garry Nolan, PhD · Stanford University

  • Ann Arvin, MD · Stanford University

  • Stephen Quake, PhD · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2013-01-31
Completion
2013-01-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03022435 on ClinicalTrials.gov